Skip to main content

Lantheus Holdings, Inc. (LNTH) Stock Analysis

HoldModerate Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Hold if already holding. Not a fresh buy at $92.89, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Jubilant HollisterStier; Concentration risk — Product: PYLARIFY.

Lantheus Holdings is a radiopharmaceutical-focused company with three product categories: Radiopharmaceutical Oncology (PYLARIFY, F-18 PSMA PET for prostate cancer), Precision Diagnostics (DEFINITY ultrasound agent, Neuraceq Alzheimer's PET), and Strategic Partnerships/CDMO.... Read more

$92.89+3.7% A.UpsideScore 6.2/10#6 of 29 Drug Manufacturers - Specialty & Generic
QualityF-score9 / 9FCF yield6.96%
Stop $86.39Target $96.30(resistance)A.R:R -0.2:1
Analyst target$104.08+12.0%13 analysts
$96.30our TP
$92.89price
$104.08mean
$76
$117

Hold if already holding. Not a fresh buy at $92.89, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Jubilant HollisterStier; Concentration risk — Product: PYLARIFY. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 6.2/10, moderate confidence.

Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.

Val6.4Qual8.4Grw6.4Mom5.7Sent7.0Ins5.0Peer3.6Tech4.4Risk5.76.2OVERALL

Recent Developments — Lantheus Holdings, Inc.

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
V7 flight-to-quality bonus: +0.5 (Q=8.4 in RISK_OFF)
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (3/4)
Risks
Concentration risk — Supplier: Jubilant HollisterStier
Concentration risk — Product: PYLARIFY
Analyst target reached - limited upside remaining

Key Metrics

P/E (TTM)22.2
P/E (Fwd)14.6
Mkt Cap$6.1B
EV/EBITDA16.9
Profit Mgn18.0%
ROE23.5%
Rev Growth1.2%
Beta-0.08
DividendNone
Rating analysts19

Quality Signals

Piotroski F9/9MoatNarrow

Options Flow

P/C0.28bullish
IV41%normal

Concentration Risks(10-K Item 1A)

  • HIGHSupplierJubilant HollisterStier
    10-K Item 1A: 'We rely on Jubilant HollisterStier as a substantial supplier of DEFINITY.'
  • HIGHProductPYLARIFY
    10-K Item 1A: 'Continued substantial revenue contribution from PYLARIFY is dependent on (A) the ability of positron emission tomography ("PET") manufacturing facilities ("PMFs") to manufacture PYLARIFY to meet product demand'

Material Events(8-K, last 90d)

  • 2026-05-01Item 5.02LOW
    Lantheus shareholders approved the Amended and Restated 2026 Equity Incentive Plan on April 30, 2026, adding 2,000,000 shares, renaming the plan, and updating director compensation limits. No officer departure or appointment.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
3.0
Value Rank
3.6
Quality Rank
7.7
GatesA.R:R -0.2=NEGATIVEMomentum 5.7>=5.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 78d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Moderate
RSI
75 · Overbought
↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $80.00Resistance $98.27

Price Targets

$86
$96
A.Upside+3.7%
A.R:R-0.2:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! Target reached (-2.5% upside)
! Negative risk/reward — downside exceeds upside

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-08-05 (78d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is LNTH stock a buy right now?

Hold if already holding. Not a fresh buy at $92.89, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Jubilant HollisterStier; Concentration risk — Product: PYLARIFY. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $96.30 (+3.7%), stop $86.39 (−7.5%), A.R:R -0.2:1. Score 6.2/10, moderate confidence.

What is the LNTH stock price target?

Take-profit target: $96.30 (+3.7% upside). Target $96.30 (+3.7%), stop $86.39 (−7.5%), A.R:R -0.2:1. Stop-loss: $86.39.

What are the risks of investing in LNTH?

Concentration risk — Supplier: Jubilant HollisterStier; Concentration risk — Product: PYLARIFY; Analyst target reached - limited upside remaining.

Is LNTH overvalued or undervalued?

Lantheus Holdings, Inc. trades at a P/E of 22.2 (forward 14.6). TrendMatrix value score: 6.4/10. Verdict: Hold.

What do analysts say about LNTH?

19 analysts cover LNTH with a consensus score of 4.1/5. Average price target: $104.

What does Lantheus Holdings, Inc. do?Lantheus Holdings is a radiopharmaceutical-focused company with three product categories: Radiopharmaceutical Oncology...

Lantheus Holdings is a radiopharmaceutical-focused company with three product categories: Radiopharmaceutical Oncology (PYLARIFY, F-18 PSMA PET for prostate cancer), Precision Diagnostics (DEFINITY ultrasound agent, Neuraceq Alzheimer's PET), and Strategic Partnerships/CDMO. Products are sold primarily in the U.S. to hospitals, imaging centers, and government facilities through a network of third-party PMFs.

Related stocks: NBIX (Neurocrine Biosciences, Inc.) · INDV (Indivior Pharmaceuticals, Inc.) · ANIP (ANI Pharmaceuticals, Inc.) · BHC (Bausch Health Companies Inc.) · COLL (Collegium Pharmaceutical, Inc.)